Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study-Reference-Cited by-同舟云学术

Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study

Published:2019-07-03 Issue:11 Volume:126 Page:1338-1345
ISSN:1470-0328
Container-title:BJOG: An International Journal of Obstetrics & Gynaecology
language:en
Short-container-title:BJOG: Int J Obstet Gy

Author:

Money D¹,Lee T²,O'Brien C³,Brophy J⁴,Bitnun A⁵,Kakkar F⁶,Boucoiran I⁷,Alimenti A¹,Vaudry W⁷,Singer J²,Sauve LJ¹³^ORCID,

Affiliation:

1. Women's Hospital and Health Centre of British Columbia University of British Columbia Vancouver BC Canada

2. CIHR Canadian HIV Trials Network Vancouver BC Canada

3. BC Children's Hospital University of British Columbia Vancouver BC Canada

4. Children's Hospital of Eastern Ontario University of Ottawa Ottawa ON Canada

5. Hospital for Sick Children University of Toronto Toronto ON Canada

6. CHU Ste‐JustineUniversité de Montréal Montréal QC Canada

7. Stollery Children's Hospital University of Alberta Edmonton AB Canada

Publisher

Wiley

Subject

Obstetrics and Gynaecology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1471-0528.15838

Reference23 articles.

1. Searo HamptonG.Update on antiretroviral regimens for treating and preventing HIV infection and update on early infant diagnosis of HIV policy brief. HIV treatment – interim guidance. WHO. [Internet].2018 vol. 11. Available fromhttp://www.who.int/iris/handle/10665/273129. Accessed 15 October 2018.

2. World Health Organization.Transition to new antiretrovirals in HIV programmes. WHO [Internet].2017;(July):vol. 8. Available fromhttp://www.who.int/hiv/pub/toolkits/transition-to-new-arv/en/. Accessed 15 October 2018.

3. World Health Organization.Updated recommendations on first‐line and second‐line antiretroviral regimens and post‐exposure prophylaxis and recommendations on early infant diagnosis of HIV policy brief. HIV Treatment‐Interim Guidance. WHO. [Internet].2018;(July):13. Available fromhttp://www.who.int/iris/handle/10665/273632. Accessed 15 October 2018.

4. Dolutegravir for HIV: a lesson in pregnancy safety research

5. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®;Pharmacology Research & Perspectives;2024-07-31

2. First-trimester exposure to newer antiretroviral agents and congenital anomalies in a US cohort;AIDS;2024-06-11

3. Directive clinique no 450 : Prise en charge des femmes enceintes vivant avec le VIH et interventions pour réduire le risque de transmission périnatale;Journal of Obstetrics and Gynaecology Canada;2024-06

4. Guideline No. 450: Care of Pregnant Women Living with HIV and Interventions to Reduce Perinatal Transmission;Journal of Obstetrics and Gynaecology Canada;2024-06

5. Dolutegravir induces FOLR1 expression during brain organoid development;Frontiers in Molecular Neuroscience;2024-05-17